Verteporfin is primarily used in a medical treatment known as photodynamic therapy (PDT) for certain eye conditions. It is specifically applied in the management of age-related macular degeneration (AMD), particularly the wet form, where abnormal blood vessels grow under the retina and macula, leading to vision loss.

In this therapy, Verteporfin is injected into the patient's bloodstream and then activated by a non-thermal laser light directed at the affected area of the eye. This activation produces a form of oxygen that destroys the abnormal blood vessels, thereby slowing the progression of vision loss.

Additionally, Verteporfin is utilized in the treatment of pathological myopia and presumed ocular histoplasmosis syndrome, where similar abnormal blood vessel growth occurs. Its targeted action helps preserve vision by minimizing damage to the surrounding healthy retinal tissue.

Overall, Verteporfin plays a critical role in ophthalmology, offering a non-invasive treatment option for patients with specific retinal disorders.